Neeraj Agarwal’s highlights from ESMO24

The ESMO Congress 2024 (ESMO24) is one of the most globally influential platforms in oncology, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from across the world.

Held from 13-17 September 2024, in Barcelona and through a Virtual Congress Platform, ESMO24 will serve as a critical hub for the dissemination of the latest cutting-edge cancer research, offering high-quality education and dynamic networking opportunities.

In connection to that, Neeraj Agarwal shared several valuable posts from ESMO24 on his X account:

TiNivo-2 Phase 3 Trial Results in Metastatic Renal Cell Carcinoma

“First results of the phase 3 TiNivo-2 in metastatic renal cell carcinoma at the ESMO24 by Toni Choueiri.
No evidence of improved outcome with re-treatment with an immune checkpoint inhibitor. 

Trial confirmed data from Contact-2 trial.”

Sunniforecast Trial

“First results of the randomized Sunniforecast trial in non-clear cell mRCC (n=306) at the ESMO24  by Dr. Lothar Bergmann

Ipilimumab + nivolumab improved OS (not PFS) compared to VEGF TKI control.”

Litespark-005 Phase 3 Trial

“Final analysis of the ph3 Litespark -005 trial with belzutifan in mRCC at the ESMO24 by Brian Rini.

PFS remains significant
OS is similar in both arms.”

NKT2152 in metastatic RCC

“A novel HIF-2 alpha inhibitor, NKT2152  in mRCC in ESMO24.

Encouraging efficacy and safety in this ph1/2 trial of heavily treated patients.
Excellent talk by Eric Jonasch.”

Exploring Novel Targets in Bladder and Kidney Cancer

“Excellent discussion on novel targets in bladder cancer and kidney cancer by Jonathan Rosenberg in ESMO24.

New Her-2 targeting ADC and a new HIF-2 inhibitor.”

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.

Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.

For more latest updates on ESMO24, visit OncoDaily.